Research ExplorerPublicationsAnticancer activity of a lectin-rich mistletoe extract injec...

Anticancer activity of a lectin-rich mistletoe extract injected intratumorally into human pancreatic cancer xenografts

Standard

Anticancer activity of a lectin-rich mistletoe extract injected intratumorally into human pancreatic cancer xenografts. / Rostock, M; Huber, R; Greiner, T; Fritz, P; Scheer, R; Schueler, J; Fiebig, H H.

In: ANTICANCER RES, Vol. 25, No. 3B, 15.09.2005, p. 1969-75.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Rostock, M, Huber, R, Greiner, T, Fritz, P, Scheer, R, Schueler, J & Fiebig, HH 2005, 'Anticancer activity of a lectin-rich mistletoe extract injected intratumorally into human pancreatic cancer xenografts', ANTICANCER RES, vol. 25, no. 3B, pp. 1969-75.

APA

Rostock, M., Huber, R., Greiner, T., Fritz, P., Scheer, R., Schueler, J., & Fiebig, H. H. (2005). Anticancer activity of a lectin-rich mistletoe extract injected intratumorally into human pancreatic cancer xenografts. ANTICANCER RES, 25(3B), 1969-75.

Vancouver

Rostock M, Huber R, Greiner T, Fritz P, Scheer R, Schueler J et al. Anticancer activity of a lectin-rich mistletoe extract injected intratumorally into human pancreatic cancer xenografts. ANTICANCER RES. 2005 Sep 15;25(3B):1969-75.

Bibtex

@article{0e50eb3a152e4e15bea2e113ef9e1573,
title = "Anticancer activity of a lectin-rich mistletoe extract injected intratumorally into human pancreatic cancer xenografts",
abstract = "BACKGROUND: In single case observations, tumour remissions after intratumoral injections of mistletoe extracts have been described.MATERIALS AND METHODS: We investigated the antitumour activity of intratumorally (i.t.)-injected lectin-rich mistletoe extract at different dosages and i.t.-injected mistletoe lectin I in comparison to intravenous (i.v.) Gemcitabine and i.t. treatment with placebo in a human pancreatic cancer xenograft.RESULTS: In a preliminary dose-response experiment, the most marked tumour inhibition was induced when mistletoe extract was given at 8 mg/kg body weight (BW) and mistletoe lectin I at 5.3 microg/kg BW. In a second experiment, bi-weekly i.t. injections of mistletoe extract over 8 weeks resulted in a very high antitumour activity with an optimal T/C value (=median relative tumour volume of the test group vs. the control) of 0.4% combined with 3/8 partial and 3/8 complete remissions. Gemcitabine was less active with 2/8 partial and 1/8 complete remissions and an optimal TIC of 4.6%.CONCLUSION: I.t.-injected lectin-rich mistletoe extract should be further evaluated in patients with inoperable locally advanced pancreatic cancer.",
keywords = "Adenocarcinoma/drug therapy, Animals, Antimetabolites, Antineoplastic/pharmacology, Antineoplastic Agents, Phytogenic/administration & dosage, Cell Line, Tumor, Deoxycytidine/analogs & derivatives, Dose-Response Relationship, Drug, Female, Humans, Injections, Intralesional, Male, Mice, Mice, Nude, Pancreatic Neoplasms/drug therapy, Plant Preparations/administration & dosage, Plant Proteins/administration & dosage, Remission Induction, Ribosome Inactivating Proteins, Type 2, Toxins, Biological/administration & dosage, Xenograft Model Antitumor Assays",
author = "M Rostock and R Huber and T Greiner and P Fritz and R Scheer and J Schueler and Fiebig, {H H}",
year = "2005",
month = sep,
day = "15",
language = "English",
volume = "25",
pages = "1969--75",
journal = "ANTICANCER RES",
issn = "0250-7005",
publisher = "International Institute of Anticancer Research",
number = "3B",

}

RIS

TY - JOUR

T1 - Anticancer activity of a lectin-rich mistletoe extract injected intratumorally into human pancreatic cancer xenografts

AU - Rostock, M

AU - Huber, R

AU - Greiner, T

AU - Fritz, P

AU - Scheer, R

AU - Schueler, J

AU - Fiebig, H H

PY - 2005/9/15

Y1 - 2005/9/15

N2 - BACKGROUND: In single case observations, tumour remissions after intratumoral injections of mistletoe extracts have been described.MATERIALS AND METHODS: We investigated the antitumour activity of intratumorally (i.t.)-injected lectin-rich mistletoe extract at different dosages and i.t.-injected mistletoe lectin I in comparison to intravenous (i.v.) Gemcitabine and i.t. treatment with placebo in a human pancreatic cancer xenograft.RESULTS: In a preliminary dose-response experiment, the most marked tumour inhibition was induced when mistletoe extract was given at 8 mg/kg body weight (BW) and mistletoe lectin I at 5.3 microg/kg BW. In a second experiment, bi-weekly i.t. injections of mistletoe extract over 8 weeks resulted in a very high antitumour activity with an optimal T/C value (=median relative tumour volume of the test group vs. the control) of 0.4% combined with 3/8 partial and 3/8 complete remissions. Gemcitabine was less active with 2/8 partial and 1/8 complete remissions and an optimal TIC of 4.6%.CONCLUSION: I.t.-injected lectin-rich mistletoe extract should be further evaluated in patients with inoperable locally advanced pancreatic cancer.

AB - BACKGROUND: In single case observations, tumour remissions after intratumoral injections of mistletoe extracts have been described.MATERIALS AND METHODS: We investigated the antitumour activity of intratumorally (i.t.)-injected lectin-rich mistletoe extract at different dosages and i.t.-injected mistletoe lectin I in comparison to intravenous (i.v.) Gemcitabine and i.t. treatment with placebo in a human pancreatic cancer xenograft.RESULTS: In a preliminary dose-response experiment, the most marked tumour inhibition was induced when mistletoe extract was given at 8 mg/kg body weight (BW) and mistletoe lectin I at 5.3 microg/kg BW. In a second experiment, bi-weekly i.t. injections of mistletoe extract over 8 weeks resulted in a very high antitumour activity with an optimal T/C value (=median relative tumour volume of the test group vs. the control) of 0.4% combined with 3/8 partial and 3/8 complete remissions. Gemcitabine was less active with 2/8 partial and 1/8 complete remissions and an optimal TIC of 4.6%.CONCLUSION: I.t.-injected lectin-rich mistletoe extract should be further evaluated in patients with inoperable locally advanced pancreatic cancer.

KW - Adenocarcinoma/drug therapy

KW - Animals

KW - Antimetabolites, Antineoplastic/pharmacology

KW - Antineoplastic Agents, Phytogenic/administration & dosage

KW - Cell Line, Tumor

KW - Deoxycytidine/analogs & derivatives

KW - Dose-Response Relationship, Drug

KW - Female

KW - Humans

KW - Injections, Intralesional

KW - Male

KW - Mice

KW - Mice, Nude

KW - Pancreatic Neoplasms/drug therapy

KW - Plant Preparations/administration & dosage

KW - Plant Proteins/administration & dosage

KW - Remission Induction

KW - Ribosome Inactivating Proteins, Type 2

KW - Toxins, Biological/administration & dosage

KW - Xenograft Model Antitumor Assays

M3 - SCORING: Journal article

C2 - 16158932

VL - 25

SP - 1969

EP - 1975

JO - ANTICANCER RES

JF - ANTICANCER RES

SN - 0250-7005

IS - 3B

ER -